Exploration of backbone space in foldamers containing α- and β-amino acid residues:: Developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-xL

被引:68
作者
Sadowsky, Jack D.
Murray, Justin K.
Tomita, York
Gellman, Samuel H.
机构
[1] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA
[2] Georgetown Univ, Ctr Med, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA
关键词
foldamers; helical structures; parallel synthesis; peptidomimetics; protein-protein interactions;
D O I
10.1002/cbic.200600546
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein-protein interactions play crucial roles in cell-signaling events and are often implicated in human disease. Molecules that bind tightly to functional protein-surface sites and show hgih stability to degradative enzymes could be valuable pharmacological tools for dissection of cell-signaling networks and might ultimately lead to thereapeutic agents. We recently described oligomers containing both alpha- and beta-amino acid residues that bind tightly to the BH3 recognition site of the anti-apoptotic protein Bcl-x(L). The oligomers with the highest affinity had a nine-residue N-terminal segment with a 1:1 alpha:beta residue repeat and a six-residue C-terminal segment containing exclusively proteinogenic alpha-residues. The N-terminal portions of such (alpha/beta + alpha)-peptides are highly resistant to proteolysis, but the C-terminal alpha-segments are susceptible. This study emerged from efforts to modify the alpha-segment in an (alpha/beta + alpha)-peptide in a way that would diminish proteolytic degradation but retain high affinity for Bcl-x(L). Some of the oligomers reported here could prove useful in certain biological applications, particularly those for which extended incubation in a biological milieu is required.
引用
收藏
页码:903 / 916
页数:14
相关论文
共 84 条
[1]   Exploiting natural peptide diversity:: novel research tools and drug leads [J].
Adermann, K ;
John, H ;
Ständker, L ;
Forssmann, WG .
CURRENT OPINION IN BIOTECHNOLOGY, 2004, 15 (06) :599-606
[2]   Converting a peptide into a drug: Strategies to improve stability and bioavailability [J].
Adessi, C ;
Soto, C .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) :963-978
[3]   Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream [J].
Arkin, MR ;
Wells, JA .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :301-317
[4]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[5]   Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs [J].
Baell, JB ;
Huang, DCS .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :851-863
[6]   Modulation of protein-protein interactions with small organic molecules [J].
Berg, T .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (22) :2462-2481
[7]  
Berg T., 2003, ANGEW CHEM, V115, P2566
[8]   Anatomy of hot spots in protein interfaces [J].
Bogan, AA ;
Thorn, KS .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 280 (01) :1-9
[9]   Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members [J].
Certo, Michael ;
Moore, Victoria Del Gaizo ;
Nishino, Mari ;
Wei, Guo ;
Korsmeyer, Stanley ;
Armstrong, Scott A. ;
Letai, Anthony .
CANCER CELL, 2006, 9 (05) :351-365
[10]   Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function [J].
Chen, L ;
Willis, SN ;
Wei, A ;
Smith, BJ ;
Fletcher, JI ;
Hinds, MG ;
Colman, PM ;
Day, CL ;
Adams, JM ;
Huang, DCS .
MOLECULAR CELL, 2005, 17 (03) :393-403